CD19 and mantle cell lymphoma: Additionally, brexucabtagene autoleucel (brexu-cel), another second-generation CD19 CAR-T cell product, has been authorized for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and B-ALL (8, 9).